- cafead   Aug 07, 2024 at 11:42: AM
via Among the biopharmas eager to find a novel treatment for depression is Autobahn Therapeutics, a San Diego-based biotech with one candidate in the clinic looking at both MDD and bipolar disorder depression. Its lead candidate ABX-002 is a selective thyroid hormone beta receptor agonist that is about to enter phase 2 clinical trials for both indications.
article source
article source